Transgene Biotek Limited (BOM:526139)
India
· Delayed Price · Currency is INR 2.880
+0.010 (0.35%)
At close: Apr 28, 2026
Transgene Biotek Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 2.33 | 2.61 | 2.35 | 0.55 | 0.87 | 1.7 | Upgrade
|
| Revenue Growth (YoY) | 1.73% | 10.98% | 326.32% | -36.44% | -48.87% | 4642.12% | Upgrade
|
| Cost of Revenue | - | - | 0.03 | 0.66 | -0.45 | 0.64 | Upgrade
|
| Gross Profit | 2.33 | 2.61 | 2.32 | -0.11 | 1.32 | 1.05 | Upgrade
|
| Selling, General & Admin | 1.84 | 3.15 | 3.18 | 3.04 | 2.93 | 2.5 | Upgrade
|
| Other Operating Expenses | 8.54 | 10.68 | 5.2 | 7.38 | 3 | 3.77 | Upgrade
|
| Operating Expenses | 12.11 | 14.77 | 9.3 | 59.91 | 105.17 | 105.36 | Upgrade
|
| Operating Income | -9.78 | -12.16 | -6.98 | -60.03 | -103.85 | -104.31 | Upgrade
|
| Interest Expense | -9.75 | -2.44 | -1.4 | -1.81 | -2.29 | -2.71 | Upgrade
|
| Other Non Operating Income (Expenses) | -5.64 | 1.75 | 1.75 | 1.75 | 1.75 | 1.75 | Upgrade
|
| EBT Excluding Unusual Items | -25.17 | -12.84 | -6.63 | -60.09 | -104.39 | -105.26 | Upgrade
|
| Other Unusual Items | 6.08 | 6.08 | 0.07 | - | 0.37 | 0.92 | Upgrade
|
| Pretax Income | -19.09 | -6.76 | -6.56 | -60.09 | -104.02 | -104.35 | Upgrade
|
| Net Income | -19.09 | -6.76 | -6.56 | -60.09 | -104.02 | -104.35 | Upgrade
|
| Net Income to Common | -19.09 | -6.76 | -6.56 | -60.09 | -104.02 | -104.35 | Upgrade
|
| Shares Outstanding (Basic) | 76 | 76 | 76 | 76 | 76 | 76 | Upgrade
|
| Shares Outstanding (Diluted) | 76 | 76 | 76 | 76 | 76 | 76 | Upgrade
|
| EPS (Basic) | -0.25 | -0.09 | -0.09 | -0.79 | -1.37 | -1.38 | Upgrade
|
| EPS (Diluted) | -0.25 | -0.09 | -0.09 | -0.79 | -1.37 | -1.38 | Upgrade
|
| Free Cash Flow | - | -5.04 | 0.05 | -0.01 | 0.98 | -0.15 | Upgrade
|
| Free Cash Flow Per Share | - | -0.07 | 0.00 | - | 0.01 | -0.00 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 98.72% | -20.33% | 152.09% | 62.05% | Upgrade
|
| Operating Margin | -419.21% | -466.40% | -297.32% | -10894.01% | -11979.30% | -6151.93% | Upgrade
|
| Profit Margin | -818.61% | -259.34% | -279.06% | -10904.90% | -11998.40% | -6154.34% | Upgrade
|
| Free Cash Flow Margin | - | -193.21% | 1.96% | -2.36% | 112.81% | -8.74% | Upgrade
|
| EBITDA | -8.84 | -11.23 | -6.06 | -10.53 | -4.61 | -5.23 | Upgrade
|
| EBITDA Margin | - | - | -258.02% | - | - | - | Upgrade
|
| D&A For EBITDA | 0.94 | 0.93 | 0.92 | 49.5 | 99.24 | 99.08 | Upgrade
|
| EBIT | -9.78 | -12.16 | -6.98 | -60.03 | -103.85 | -104.31 | Upgrade
|
| EBIT Margin | - | - | -297.32% | - | - | - | Upgrade
|
| Revenue as Reported | 2.77 | 10.44 | 4.18 | 2.31 | 2.99 | 4.36 | Upgrade
|
| Advertising Expenses | - | 0.01 | 0.02 | 0.02 | 0.04 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.